IQVIA Holdings Inc. (NYSE:IQV) Short Interest Up 11.0% in December

IQVIA Holdings Inc. (NYSE:IQV) was the target of a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 3,120,000 shares, a growth of 11.0% from the December 15th total of 2,810,000 shares. Based on an average daily trading volume, of 1,530,000 shares, the days-to-cover ratio is presently 2.0 days. Approximately 1.7% of the company’s stock are short sold.

IQVIA Stock Performance

Shares of IQV stock traded down $0.41 during trading hours on Monday, hitting $197.25. The company’s stock had a trading volume of 1,253,280 shares, compared to its average volume of 1,057,891. The stock has a market cap of $35.80 billion, a PE ratio of 25.89, a price-to-earnings-growth ratio of 2.09 and a beta of 1.48. The company has a 50 day moving average of $200.09 and a 200 day moving average of $221.39. IQVIA has a 12-month low of $187.62 and a 12-month high of $261.73. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76.

Hedge Funds Weigh In On IQVIA

A number of institutional investors have recently modified their holdings of IQV. Capital Performance Advisors LLP acquired a new stake in IQVIA during the third quarter valued at $27,000. Park Place Capital Corp purchased a new stake in shares of IQVIA in the third quarter valued at approximately $28,000. Itau Unibanco Holding S.A. acquired a new position in shares of IQVIA during the 2nd quarter worth approximately $29,000. Avior Wealth Management LLC lifted its position in shares of IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after buying an additional 87 shares in the last quarter. Finally, Assetmark Inc. grew its stake in IQVIA by 612.5% in the 3rd quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock valued at $54,000 after acquiring an additional 196 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have issued reports on IQV shares. Truist Financial dropped their target price on shares of IQVIA from $265.00 to $261.00 and set a “buy” rating on the stock in a report on Thursday, December 12th. Evercore ISI dropped their target price on IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. Bank of America reduced their price target on IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a research report on Friday, December 13th. BTIG Research dropped their price objective on IQVIA from $290.00 to $260.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Finally, StockNews.com downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a report on Thursday, November 28th. Four analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $255.82.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.